Strategic dermatology clinical operations during the coronavirus disease 2019 (COVID-19) pandemic - 24/04/20
Doi : 10.1016/j.jaad.2020.03.089
Kyla N. Price, BS a, Rebecca Thiede, MD b, Vivian Y. Shi, MD b, Clara Curiel-Lewandrowski, MD b, ⁎ 
a University of Illinois Chicago, College of Medicine
b Division of Dermatology, Department of Medicine, University of Arizona, Tucson
∗Correspondence to: Clara Curiel-Lewandrowski, MD, University of Arizona, 7165 N. Pima Canyon Dr, Tucson, AZ 85718University of Arizona7165 N. Pima Canyon DrTucsonAZ85718
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 24 April 2020
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Shi is a stock shareholder of Learn Health and has served as an advisory board member and/or investigator and/or has received research funding from Sanofi Genzyme, Regeneron, AbbVie, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Menlo Therapeutics, Burt’s Bees, GpSkin, Altus Labs, and Skin Actives Scientific; there were no incentives or transactions, financial or otherwise, relevant to this manuscript. Dr Curiel-Lewandrowski has served as an advisory board member and/or investigator and/or has received research funding from Amgen, Bristol-Myers Squibb, Helsinn, and Novartis; there were no incentives or transactions, financial or otherwise, relevant to this manuscript. Ms Price and Dr Thiede have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.